Breast Cancer | Specialty

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017

Multidisciplinary Team in Soft Tissue Sarcoma

November 14th 2017

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Dr. Melisko on the MA.17R Study for ER+ Breast Cancer

November 10th 2017

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

Dr. Finn on the Revolution of CDK4/6 Inhibition in HR+ Breast Cancer

November 10th 2017

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

November 9th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Ribociclib Improved PFS for Women with HR+/HER2- Breast Cancer

November 8th 2017

Topline results from the MONALESSA-7 trial showed that ribociclib met its primary endpoint for progression-free survival in premenopausal women with hormone-receptor

Dr. Majure on Unmet Needs for Patients With TNBC

November 8th 2017

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Expert Expands on Decision-Making Impact of Genetic Testing in Breast Cancer

November 1st 2017

Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated

November 1st 2017

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Expert Raises QoL Concerns With Adjuvant Hormonal Therapy in ER+ Breast Cancer

October 31st 2017

Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.

CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers

October 31st 2017

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Neoadjuvant Treatment Evolving in HER2-Positive Breast Cancer

October 31st 2017

Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.